Edition:
India

BeiGene Ltd (BGNE.OQ)

BGNE.OQ on NASDAQ Stock Exchange Global Select Market

87.53USD
24 Nov 2017
Change (% chg)

$1.45 (+1.68%)
Prev Close
$86.08
Open
$86.39
Day's High
$87.98
Day's Low
$85.84
Volume
63,672
Avg. Vol
106,858
52-wk High
$118.71
52-wk Low
$26.58

Latest Key Developments (Source: Significant Developments)

Beigene Ltd qtrly ‍net income attributable to common shareholders per ADS, diluted $2.54​
Tuesday, 14 Nov 2017 

Nov 13 (Reuters) - Beigene Ltd ::Beigene reports third quarter 2017 financial results.Beigene Ltd - qtrly ‍net income attributable to common shareholders per ads, diluted $2.54​.  Full Article

Beigene receives approval to initiate clinical trials in China
Thursday, 18 Aug 2016 

Beigene Ltd : Beigene receives approval to initiate clinical trials in china with parp inhibitor BGB-290 .Received clinical trial application approval from China Food And Drug Administration (CFDA) to conduct clinical trials in China with BGB-290.  Full Article

Beigene Q2 earnings per share view $-0.68, revenue view $1.4 mln -- Thomson Reuters I/B/E/S
Thursday, 11 Aug 2016 

Beigene Ltd : Beigene reports second quarter 2016 financial results . Qtrly net loss per ads $0.73 . Revenue for three months ended June 30, 2016 was $0.39 million, compared to $1.38 million for three months ended June 30, 2015 .Q2 earnings per share view $-0.68, revenue view $1.4 million -- Thomson Reuters I/B/E/S.  Full Article

Beigene reports Q1 loss per share $0.97
Thursday, 12 May 2016 

Beigene Ltd : Qtrly loss per share $0.97 . Revenue for the three months ended march 31, 2016 was $0.68 million, compared to $1.38 million for the three months ended march 31, 2015 .Beigene reports first quarter 2016 financial results.  Full Article